libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karzinom, plattenepithelkarzinom - antineoplastische mittel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
irinotecan sun 1,5 mg/ml infusionslösung
sun pharmaceuticals germany gmbh (8127792) - irinotecanhydrochlorid 3 h<2>o - infusionslösung - 1,5 mg/ml - teil 1 - infusionslösung; irinotecanhydrochlorid 3 h<2>o (28859) 1,5 milligramm
irinotecan kelix bio 20 mg/ml konzentrat zur herstellung einer infusionslösung
kelix bio (malta) ltd. (1010499) - irinotecanhydrochlorid 3 h<2>o - konzentrat zur herstellung einer infusionslösung - 20 mg/ml irinotecanhydrochlorid 3 h<2>o - teil 1 - konzentrat zur herstellung einer infusionslösung; irinotecanhydrochlorid 3 h<2>o (28859) 20 milligramm
irinotecan phares 20 mg/ml konzentrat zur herstellung einer infusionslösung
pharma resources gmbh (8139312) - irinotecanhydrochlorid 3 h<2>o - konzentrat zur herstellung einer infusionslösung - 20 mg/ml irinotecanhydrochlorid 3 h<2>o - teil 1 - konzentrat zur herstellung einer infusionslösung; irinotecanhydrochlorid 3 h<2>o (28859) 20 milligramm
irinotecan amarox 20 mg/ml konzentrat zur herstellung einer infusionslösung
amarox pharma gmbh (8110952) - konzentrat zur herstellung einer infusionslösung - 20 mg/ml
fentanyl hexal 25 µg/h - depotpflaster
hexal pharma gmbh - fentanyl - fentanyl
fentanyl 1a pharma 75 µg/h - depotpflaster
1a pharma gmbh - fentanyl - fentanyl
fentanyl 1a pharma 100 µg/h - depotpflaster
1a pharma gmbh - fentanyl - fentanyl
fentanyl 1a pharma 25 µg/h - depotpflaster
1a pharma gmbh - fentanyl - fentanyl
fentanyl hexal 75 µg/h - depotpflaster
hexal pharma gmbh - fentanyl - fentanyl